December 7, 2018
Each of the many BCMA-targeted chimeric antigen receptor (CAR) T cells in development demonstrate a different efficacy and safety profile, and each have different constructs. None of the agents have reached the FDA yet, but data for many of the agents were presented at the 2018 ASH Annual Meeting. Showing promising data in the phase...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand